Age 0 3 0 3 B-age
≥18 4 7 4 7 O
but 8 11 8 11 O
< 12 13 12 13 O
70 13 15 13 15 B-upper_bound
yrs 16 19 16 19 I-upper_bound

Any 0 3 20 23 O
stage 4 9 24 29 O
of 10 12 30 32 O
disease 13 20 33 40 O
will 21 25 41 45 O
be 26 28 46 48 O
considered 29 39 49 59 O
for 40 43 60 63 O
transplantation 44 59 64 79 B-treatment

Chemotherapy 0 12 80 92 B-treatment
or 13 15 93 95 O
radiotherapy 16 28 96 108 B-treatment
within 29 35 109 115 O
14 36 38 116 118 B-upper_bound
days 39 43 119 123 I-upper_bound
of 44 46 124 126 O
initiating 47 57 127 137 O
treatment 58 67 138 147 B-treatment
in 68 70 148 150 O
this 71 75 151 155 O
study 76 81 156 161 O
with 82 86 162 166 O
the 87 90 167 170 O
exception 91 100 171 180 O
of 101 103 181 183 O
lenalidomide 104 116 184 196 B-treatment
, 116 117 196 197 O
decitabine 118 128 198 208 B-treatment
, 128 129 208 209 O
azacitidine 130 141 210 221 B-treatment
, 141 142 221 222 O
imatinib 143 151 223 231 B-treatment
mesylate 152 160 232 240 I-treatment
, 160 161 240 241 O
dasatinib 162 171 242 251 B-treatment
, 171 172 251 252 O
nilotinib 173 182 253 262 B-treatment
hydrochloride 183 196 263 276 I-treatment
and 197 200 277 280 O
hydroxyurea 201 212 281 292 B-treatment

Confirmation 0 12 293 305 O
that 13 17 306 310 O
the 18 21 311 314 O
subject 22 29 315 322 O
is 30 32 323 325 O
not 33 36 326 329 B-pregnancy
pregnant 37 45 330 338 I-pregnancy
must 46 50 339 343 O
be 51 53 344 346 O
established 54 65 347 358 O
by 66 68 359 361 O
a 69 70 362 363 O
negative 71 79 364 372 B-pregnancy
serum 80 85 373 378 I-pregnancy
β 86 87 379 380 I-pregnancy
- 87 88 380 381 I-pregnancy
human 88 93 381 386 I-pregnancy
chorionic 94 103 387 396 I-pregnancy
gonadotropin 104 116 397 409 I-pregnancy
( 117 118 410 411 I-pregnancy
β 118 119 411 412 I-pregnancy
- 119 120 412 413 I-pregnancy
hCG 120 123 413 416 I-pregnancy
) 123 124 416 417 I-pregnancy
pregnancy 125 134 418 427 I-pregnancy
test 135 139 428 432 O
result 140 146 433 439 O
obtained 147 155 440 448 O
during 156 162 449 455 O
screening 163 172 456 465 O

Diagnosed 0 9 466 475 O
or 10 12 476 478 O
treated 13 20 479 486 O
for 21 24 487 490 O
another 25 32 491 498 O
malignancy 33 43 499 509 B-cancer
within 44 50 510 516 O
3 51 52 517 518 B-upper_bound
years 53 58 519 524 I-upper_bound
of 59 61 525 527 O
enrollment 62 72 528 538 O

Diagnosis 0 9 539 548 O
of 10 12 549 551 O
acute 13 18 552 557 B-cancer
myelogenous 19 30 558 569 I-cancer
leukemia 31 39 570 578 I-cancer

Diagnosis 0 9 579 588 O
other 10 15 589 594 O
than 16 20 595 599 O
acute 21 26 600 605 B-cancer
myelogenous 27 38 606 617 I-cancer
leukemia 39 47 618 626 I-cancer
, 47 48 626 627 O
myeloproliferative 49 67 628 646 B-cancer
disorder 68 76 647 655 I-cancer
, 76 77 655 656 O
or 78 80 657 659 O
myelodysplastic 81 96 660 675 B-cancer
syndrome 97 105 676 684 I-cancer

Documented 0 10 685 695 O
hypersensitivity 11 27 696 712 O
to 28 30 713 715 O
fludarabine 31 42 716 727 B-allergy_name
or 43 45 728 730 O
melphalan 46 55 731 740 B-allergy_name
or 56 58 741 743 O
to 59 61 744 746 O
bortezomib 62 72 747 757 B-allergy_name
, 72 73 757 758 O
boron 74 79 759 764 B-allergy_name
or 80 82 765 767 O
mannitol 83 91 768 776 B-allergy_name
or 92 94 777 779 O
any 95 98 780 783 O
components 99 109 784 794 O
of 110 112 795 797 O
the 113 116 798 801 O
formulation 117 128 802 813 O

Evidence 0 8 814 822 O
of 9 11 823 825 O
hepatic 12 19 826 833 B-chronic_disease
synthetic 20 29 834 843 I-chronic_disease
dysfunction 30 41 844 855 I-chronic_disease
, 41 42 855 856 O
or 43 45 857 859 O
total 46 51 860 865 O
bilirubin 52 61 866 875 B-clinical_variable
> 62 63 876 877 O
2x 63 65 877 879 B-lower_bound
or 66 68 880 882 O
AST 69 72 883 886 B-clinical_variable
> 73 74 887 888 O
3x 74 76 888 890 B-lower_bound
UL 77 79 891 893 I-lower_bound

FVC 0 3 894 897 B-clinical_variable
, 3 4 897 898 O
FEV1 5 9 899 903 B-clinical_variable
, 9 10 903 904 O
or 11 13 905 907 O
DLCO 14 18 908 912 B-clinical_variable
< 19 20 913 914 O
50 20 22 914 916 B-upper_bound
% 22 23 916 917 I-upper_bound
of 24 26 918 920 O
predicted 27 36 921 930 O
and/or 37 43 931 937 O
receiving 44 53 938 947 O
supplementary 54 67 948 961 B-treatment
continuous 68 78 962 972 I-treatment
oxygen 79 85 973 979 I-treatment

Female 0 6 980 986 B-gender
subject 7 14 987 994 I-gender
is 15 17 995 997 O
pregnant 18 26 998 1006 B-pregnancy

KPS 0 3 1007 1010 B-clinical_variable
of 4 6 1011 1013 O
≥70 7 10 1014 1017 O
% 10 11 1017 1018 I-lower_bound

Karnofsky 0 9 1019 1028 B-clinical_variable
score 10 15 1029 1034 I-clinical_variable
< 16 17 1035 1036 O
70 17 19 1036 1038 B-upper_bound
% 19 20 1038 1039 I-upper_bound

Known 0 5 1040 1045 O
amyloid 6 13 1046 1053 B-chronic_disease
deposition 14 24 1054 1064 I-chronic_disease
in 25 27 1065 1067 O
heart 28 33 1068 1073 O

LVEF 0 4 1074 1078 B-clinical_variable
< 5 6 1079 1080 O
40 6 8 1080 1082 B-upper_bound
% 8 9 1082 1083 I-upper_bound
or 10 12 1084 1086 O
cardiac 13 20 1087 1094 B-chronic_disease
failure 21 28 1095 1102 I-chronic_disease
not 29 32 1103 1106 O
responsive 33 43 1107 1117 O
to 44 46 1118 1120 O
therapy 47 54 1121 1128 B-treatment

Life 0 4 1129 1133 B-clinical_variable
expectancy 5 15 1134 1144 I-clinical_variable
limited 16 23 1145 1152 O
by 24 26 1153 1155 O
another 27 34 1156 1163 O
co 35 37 1164 1166 O
- 37 38 1166 1167 O
morbid 38 44 1167 1173 O
illness 45 52 1174 1181 O

Measured 0 8 1182 1190 O
creatinine 9 19 1191 1201 B-clinical_variable
clearance 20 29 1202 1211 I-clinical_variable
< 30 31 1212 1213 O
20 31 33 1213 1215 B-upper_bound
ml 34 36 1216 1218 I-upper_bound
/ 36 37 1218 1219 I-upper_bound
min 37 40 1219 1222 I-upper_bound

Myocardial 0 10 1223 1233 B-chronic_disease
infarction 11 21 1234 1244 I-chronic_disease
within 22 28 1245 1251 O
6 29 30 1252 1253 B-upper_bound
months 31 37 1254 1260 I-upper_bound
prior 38 43 1261 1266 I-upper_bound
to 44 46 1267 1269 O
enrollment 47 57 1270 1280 O
or 58 60 1281 1283 O
has 61 64 1284 1287 O
New 65 68 1288 1291 B-clinical_variable
York 69 73 1292 1296 I-clinical_variable
Heart 74 79 1297 1302 I-clinical_variable
Association 80 91 1303 1314 I-clinical_variable
( 92 93 1315 1316 I-clinical_variable
NYHA 93 97 1316 1320 I-clinical_variable
) 97 98 1320 1321 I-clinical_variable
Class 99 104 1322 1327 B-lower_bound
III 105 108 1328 1331 I-lower_bound
or 109 111 1332 1334 O
IV 112 114 1335 1337 B-upper_bound
heart 115 120 1338 1343 B-chronic_disease
failure 121 128 1344 1351 I-chronic_disease
( 129 130 1352 1353 O
see 130 133 1353 1356 O
section 134 141 1357 1364 O
8.4 142 145 1365 1368 O
) 145 146 1368 1369 O

Organ 0 5 1370 1375 B-chronic_disease
dysfunction 6 17 1376 1387 I-chronic_disease

Patient 0 7 1388 1395 O
has 8 11 1396 1399 O
received 12 20 1400 1408 O
other 21 26 1409 1414 O
investigational 27 42 1415 1430 B-treatment
drugs 43 48 1431 1436 I-treatment
with 49 53 1437 1441 O
14 54 56 1442 1444 B-upper_bound
days 57 61 1445 1449 I-upper_bound
before 62 68 1450 1456 O
enrollment 69 79 1457 1467 O

Pregnancy 0 9 1468 1477 B-pregnancy
testing 10 17 1478 1485 O
is 18 20 1486 1488 O
not 21 24 1489 1492 O
required 25 33 1493 1501 O
for 34 37 1502 1505 O
post 38 42 1506 1510 O
- 42 43 1510 1511 O
menopausal 43 53 1511 1521 O
or 54 56 1522 1524 O
surgically 57 67 1525 1535 O
sterilized 68 78 1536 1546 O
women 79 84 1547 1552 B-gender

Prior 0 5 1553 1558 B-treatment
dose 6 10 1559 1563 I-treatment
- 10 11 1563 1564 I-treatment
intense 11 18 1564 1571 I-treatment
therapy 19 26 1572 1579 I-treatment
requiring 27 36 1580 1589 O
HSC 37 40 1590 1593 O
support 41 48 1594 1601 O
within 49 55 1602 1608 O
56 56 58 1609 1611 B-upper_bound
days 59 63 1612 1616 I-upper_bound
of 64 66 1617 1619 O
initiating 67 77 1620 1630 O
treatment 78 87 1631 1640 B-treatment
in 88 90 1641 1643 O
this 91 95 1644 1648 O
study 96 101 1649 1654 O

Prior 0 5 1655 1660 O
to 6 8 1661 1663 O
study 9 14 1664 1669 O
entry 15 20 1670 1675 O
, 20 21 1675 1676 O
any 22 25 1677 1680 O
ECG 26 29 1681 1684 B-treatment
abnormality 30 41 1685 1696 O
at 42 44 1697 1699 O
screening 45 54 1700 1709 O
has 55 58 1710 1713 O
to 59 61 1714 1716 O
be 62 64 1717 1719 O
documented 65 75 1720 1730 O
by 76 78 1731 1733 O
the 79 82 1734 1737 O
investigator 83 95 1738 1750 O
as 96 98 1751 1753 O
not 99 102 1754 1757 O
medically 103 112 1758 1767 O
relevant 113 121 1768 1776 O

Recovery 0 8 1777 1785 O
from 9 13 1786 1790 O
all 14 17 1791 1794 O
hematologic 18 29 1795 1806 B-chronic_disease
and 30 33 1807 1810 O
non 34 37 1811 1814 B-chronic_disease
- 37 38 1814 1815 I-chronic_disease
hematology 38 48 1815 1825 I-chronic_disease
toxicities 49 59 1826 1836 I-chronic_disease
from 60 64 1837 1841 O
previous 65 73 1842 1850 O
therapies 74 83 1851 1860 B-treatment

Serious 0 7 1861 1868 O
medical 8 15 1869 1876 O
or 16 18 1877 1879 O
psychiatric 19 30 1880 1891 B-chronic_disease
illness 31 38 1892 1899 I-chronic_disease
likely 39 45 1900 1906 O
to 46 48 1907 1909 O
interfere 49 58 1910 1919 O
with 59 63 1920 1924 O
participation 64 77 1925 1938 O
in 78 80 1939 1941 O
this 81 85 1942 1946 O
clinical 86 94 1947 1955 O
study 95 100 1956 1961 O

Uncontrolled 0 12 1962 1974 O
CNS 13 16 1975 1978 B-cancer
metastases 17 27 1979 1989 I-cancer

Uncontrolled 0 12 1990 2002 O
bacterial 13 22 2003 2012 B-chronic_disease
, 22 23 2012 2013 O
viral 24 29 2014 2019 B-chronic_disease
, 29 30 2019 2020 O
fungal 31 37 2021 2027 B-chronic_disease
or 38 40 2028 2030 O
parasitic 41 50 2031 2040 B-chronic_disease
infections 51 61 2041 2051 I-chronic_disease

breast 0 6 2052 2058 O
- 6 7 2058 2059 O
feeding 7 14 2059 2066 O
( 15 16 2067 2068 O
women 16 21 2068 2073 B-gender
) 21 22 2073 2074 O

chronic 0 7 2075 2082 B-chronic_disease
myelogenous 8 19 2083 2094 I-chronic_disease
leukemia 20 28 2095 2103 I-chronic_disease

complete 0 8 2104 2112 O
resection 9 18 2113 2122 O
of 19 21 2123 2125 O
basal 22 27 2126 2131 B-cancer
cell 28 32 2132 2136 I-cancer
carcinoma 33 42 2137 2146 I-cancer
or 43 45 2147 2149 O
squamous 46 54 2150 2158 B-cancer
cell 55 59 2159 2163 I-cancer
carcinoma 60 69 2164 2173 I-cancer
of 70 72 2174 2176 I-cancer
the 73 76 2177 2180 I-cancer
skin 77 81 2181 2185 I-cancer
, 81 82 2185 2186 O
an 83 85 2187 2189 O
in 86 88 2190 2192 B-cancer
situ 89 93 2193 2197 I-cancer
malignancy 94 104 2198 2208 I-cancer
, 104 105 2208 2209 O
or 106 108 2210 2212 O
low 109 112 2213 2216 B-cancer
- 112 113 2216 2217 I-cancer
risk 113 117 2217 2221 I-cancer
prostate 118 126 2222 2230 I-cancer
cancer 127 133 2231 2237 I-cancer
after 134 139 2238 2243 O
curative 140 148 2244 2252 B-treatment
therapy 149 156 2253 2260 I-treatment

electrocardiographic 0 20 2261 2281 B-treatment
evidence 21 29 2282 2290 O
of 30 32 2291 2293 O
acute 33 38 2294 2299 O
ischemia 39 47 2300 2308 B-chronic_disease
or 48 50 2309 2311 O
active 51 57 2312 2318 B-chronic_disease
conduction 58 68 2319 2329 I-chronic_disease
system 69 75 2330 2336 I-chronic_disease
abnormalities 76 89 2337 2350 I-chronic_disease

myelodysplastic 0 15 2351 2366 B-cancer
syndrome 16 24 2367 2375 I-cancer

other 0 5 2376 2381 O
myeloproliferative 6 24 2382 2400 B-cancer
disorder 25 33 2401 2409 I-cancer

severe 0 6 2410 2416 O
uncontrolled 7 19 2417 2429 O
ventricular 20 31 2430 2441 B-chronic_disease
arrhythmias 32 43 2442 2453 I-chronic_disease

uncontrolled 0 12 2454 2466 O
angina 13 19 2467 2473 B-chronic_disease

unwilling 0 9 2474 2483 B-contraception_consent
to 10 12 2484 2486 I-contraception_consent
use 13 16 2487 2490 I-contraception_consent
acceptable 17 27 2491 2501 I-contraception_consent
birth 28 33 2502 2507 I-contraception_consent
control 34 41 2508 2515 I-contraception_consent
methods 42 49 2516 2523 I-contraception_consent
( 50 51 2524 2525 O
men 51 54 2525 2528 B-gender
or 55 57 2529 2531 O
women 58 63 2532 2537 B-gender
) 63 64 2537 2538 O
for 65 68 2539 2542 O
twelve 69 75 2543 2549 B-upper_bound
months 76 82 2550 2556 I-upper_bound
after 83 88 2557 2562 I-upper_bound
treatment 89 98 2563 2572 B-treatment

